. Author manuscript; available in PMC: 2015 Dec 1.

Published in final edited form as: J Cancer Surviv. 2014 Jul 10;8(4):688–696. doi: 10.1007/s11764-014-0375-1

Table 3.

Positive associations for neurologic morbidity on multivariate logistic regression analyses (n=162)

Neurologic symptom	Variable	Effect	Odds ratio	95 % Confidence interval		p value
Dizziness	Gender	Female vs. male	2.01	1.01	4.0	0.05
	H/O leukemia relapse	Yes vs. no	4.81	1.02	22.71	0.05
Fatigue	H/O leukemia relapse	Yes vs. no	8.35	1.16	59.93	0.03
Urine incontinence	Gender	Female vs. male	4.49	1.64	12.26	<0.0001
	Age at Dx	Older vs. younger	0.84	0.71	0.99	0.04
	IT-chemotherapy^a	≥10 vs. <10 doses	3.61	1.31	9.95	0.01
Constipation	Gender	Female vs. male	2.33	1.05	5.16	0.04
Seizure	CNS cancer	Yes vs. no	3.03	1.05	8.73	0.04
Ataxia	Radiation	Yes vs. no	4.78	1.64	13.93	<0.0001
Back pain	IT-chemotherapy^a	≥10 vs. <10 doses	0.44	0.2	0.96	0.04
Neuropathy	Gender	Female vs. male	2.23	1.12	4.41	0.02
	IT-chemotherapy^a	≥10 vs. <10 doses	2.0	1.02	3.93	0.04

vs. versus, Dx ALL diagnosis, IT intrathecal

All participants received triple intrathecal therapy with cytarabine, methotrexate, and hydrocortisone